| Dr Sharon Ann Spak-schreiner, MD | |
|
1051 W Rand Rd # 110, Arlington Heights, IL 60004-2315 | |
| (847) 618-9292 | |
| (847) 618-9294 |
| Full Name | Dr Sharon Ann Spak-schreiner |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 39 Years |
| Location | 1051 W Rand Rd # 110, Arlington Heights, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003054289 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 036075052 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Community Hospital H | Arlington heights, IL | Home health agency |
| Northwest Community Hospital 1 | Arlington heights, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Community Health Services Inc | 3375737331 | 275 |
News Archive
OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.
A new study by University of Pennsylvania School of Medicine shows, for the first time in humans, that ventilators combined with diaphragm disuse contributes to muscle atrophy in the diaphragm in as little as eighteen hours.
Imagine if scientists could stop the coronavirus infection in its tracks simply by diverting its attention away from living lung cells? A new therapeutic countermeasure, announced in a Nano Letters study by researchers from Boston University's National Emerging Infectious Diseases Laboratories and the University of California San Diego, appears to do just that in experiments that were carried out at the NEIDL in Boston.
A national survey of recent hospital patients commissioned by TransUnion found that two-thirds of adults nationwide would like to see greater transparency in their hospital bill while only three in 10 of those surveyed were aware they could possibly qualify for charity care programs.
› Verified 5 days ago
| Entity Name | Northshore University Healthsystem Faculty Practice Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497701882 PECOS PAC ID: 2163334699 Enrollment ID: O20040524000118 |
News Archive
OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.
A new study by University of Pennsylvania School of Medicine shows, for the first time in humans, that ventilators combined with diaphragm disuse contributes to muscle atrophy in the diaphragm in as little as eighteen hours.
Imagine if scientists could stop the coronavirus infection in its tracks simply by diverting its attention away from living lung cells? A new therapeutic countermeasure, announced in a Nano Letters study by researchers from Boston University's National Emerging Infectious Diseases Laboratories and the University of California San Diego, appears to do just that in experiments that were carried out at the NEIDL in Boston.
A national survey of recent hospital patients commissioned by TransUnion found that two-thirds of adults nationwide would like to see greater transparency in their hospital bill while only three in 10 of those surveyed were aware they could possibly qualify for charity care programs.
› Verified 5 days ago
| Entity Name | Northwest Community Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134433154 PECOS PAC ID: 3375737331 Enrollment ID: O20101103000837 |
News Archive
OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.
A new study by University of Pennsylvania School of Medicine shows, for the first time in humans, that ventilators combined with diaphragm disuse contributes to muscle atrophy in the diaphragm in as little as eighteen hours.
Imagine if scientists could stop the coronavirus infection in its tracks simply by diverting its attention away from living lung cells? A new therapeutic countermeasure, announced in a Nano Letters study by researchers from Boston University's National Emerging Infectious Diseases Laboratories and the University of California San Diego, appears to do just that in experiments that were carried out at the NEIDL in Boston.
A national survey of recent hospital patients commissioned by TransUnion found that two-thirds of adults nationwide would like to see greater transparency in their hospital bill while only three in 10 of those surveyed were aware they could possibly qualify for charity care programs.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sharon Ann Spak-schreiner, MD 1051 W Rand Rd # 110, Arlington Heights, IL 60004-2315 Ph: (847) 618-9292 | Dr Sharon Ann Spak-schreiner, MD 1051 W Rand Rd # 110, Arlington Heights, IL 60004-2315 Ph: (847) 618-9292 |
News Archive
OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.
A new study by University of Pennsylvania School of Medicine shows, for the first time in humans, that ventilators combined with diaphragm disuse contributes to muscle atrophy in the diaphragm in as little as eighteen hours.
Imagine if scientists could stop the coronavirus infection in its tracks simply by diverting its attention away from living lung cells? A new therapeutic countermeasure, announced in a Nano Letters study by researchers from Boston University's National Emerging Infectious Diseases Laboratories and the University of California San Diego, appears to do just that in experiments that were carried out at the NEIDL in Boston.
A national survey of recent hospital patients commissioned by TransUnion found that two-thirds of adults nationwide would like to see greater transparency in their hospital bill while only three in 10 of those surveyed were aware they could possibly qualify for charity care programs.
› Verified 5 days ago
Chong H. Pak, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 847-618-8400 Fax: 847-618-8409 | |
Rosalina Guerrero-guzman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 675 W Central Rd, Suite 101, Arlington Heights, IL 60005 Phone: 847-342-1554 Fax: 847-342-1711 | |
Dr. Luis Fernando Soruco, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2101 S Arlington Heights Rd, 111, Arlington Heights, IL 60005 Phone: 847-228-3200 Fax: 847-228-3740 | |
Thomas F Cozzi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1430 N Arlington Heights Rd, Ste. #112, Arlington Heights, IL 60004 Phone: 847-394-9900 Fax: 847-394-1855 | |
Dr. Daniel Daeyol So, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2101 S Arlington Heights Rd, 111, Arlington Heights, IL 60005 Phone: 847-228-3200 Fax: 847-228-3740 | |
Dr. Paul A Ruzumna, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1632 W Central Rd, Arlington Heights, IL 60005 Phone: 847-618-2500 Fax: 847-253-8474 |